with HAART during the past decade has allowed researchers, clinicians, and patients to have an in-depth knowledge of factors that influence adherence. [7] [8] [9] [10] [11] [12] [13] Numerous theories related to HAART adherence have been proposed, which can be grouped into domains developed by the World Health Organization. 14 These include socioeconomic factors, health care team, system-related factors, condition-related factors, therapyrelated factors, and patient-related factors. 14 There is evidence that social support, providing adequate knowledge about adherence and resistance, HIV/AIDS symptomatology, pill burden, depressive symptoms, and substance abuse are associated with HAART adherence. 7, 15 In clinical practice, any individual may experience multiple factors that may vary over time creating difficultly in assessing adherence. Many interventions have been studied and found to be effective in increasing adherence rates. [16] [17] [18] [19] [20] [21] [22] [23] [24] These interventions are traditionally costly and multifaceted and not practical or sustainable for resource-limited clinics. There is a need for simple, validated tools for clinicians to assess patients for the potential of nonadherence.
Self-reported general health status (GHS) has been extensively used in health care research and has been found to be a reliable predictor of future mortality in populations even when accounting for known health risk factors. 25, 26 Simple GHS assessment can be ascertained through a single question, "In general, how would you rate your health?" Possible responses to this question include "excellent," "very good," "good," "fair," or "poor." According to Idler and Benyamini, 25 GHS can be interpreted as a more comprehensive measure of health status than individual covariates and a dynamic evaluation of one's current and trajectory health. GHS has a potential clinical application by assessing factors responsible for nonadherence. That is, if a patient rates his or her health as "poor," an open-ended question can then be followed, "Why do you rate your health as poor?" This leaves the clinician to address factors that are affecting the patient's health and HAART adherence. However, before this can be practiced and studied, GHS must first be proven to be associated with adherence after accounting for known covariates.
This project evaluated the relationship between GHS and HAART nonadherence among individuals living with HIV/AIDS while addressing confounding effects of other known factors. These results may potentially lead to future studies that assess GHS's clinical utility on HAART nonadherence and HIV/ AIDS mortality.
Methods Participants
This study was approved by the University of North Texas Health Science Center Institutional Review Board. This cross-sectional study recruited a convenient sample of 103 participants from the Preventive Medicine Clinic at Tarrant County Public Health in Tarrant County, Texas. The clinic accepts confirmed HIV-positive adult patients with a household income below the federal 200% poverty level. Eligible participants included individuals who self-identified themselves as white, African American, and/or Hispanic/ Latino; individuals over the age of 18 years; and individuals who were HIV positive. They were not eligible if they had a current or previous diagnosis of dementia (any form) or had been taking HAART for less than 3 months. At the completion of the clinical visit, clinicians briefly outlined the goal of the study to patients and asked potential participants if they were willing to speak to a coordinator. Subjects willing to speak to a coordinator were taken to a private room to complete the informed consent process and survey instrument. Once the survey was complete, participants were given a gift card to a national discount chain store as compensation for their time and effort. The participant's medical chart was then reviewed, and information was extracted, including medical histories, oldest and most recent CD4 cell counts, and viral load counts.
Measures
The survey included demographic measures, HAART adherence, and various psychosocial measures using validated instruments as described below. Demographic measures included age, race/ethnicity (non-Hispanic white or other), gender (male or female), and educational level (high school or less or greater than high school). Income was not reported because the clinic in which participants were recruited only accepts patients with no health insurance, Medicaid, or Medicare.
Dependent variable. HAART adherence was measured using a validated simplified medication adherence questionnaire that consisted of 6 questions related to how individuals are forgetful or careless in taking their HAART medication. 27 Validation was based on criterion validity, with comparison to electronic adherence monitoring (specificity 91% and sensitivity 72%), reliability (interobserver agreement 88.2%), and internal consistency (Cronbach's α = .75). Participants were categorized as either "adherent" or "nonadherent" to HAART based on the survey instructions. Because there may be variability in adherence measures between study populations, adherence measures were compared with viral load in the present study by conducting a univariate regression analysis as an internal validity measure. Viral load, and not CD4 count, was used because previous research found virologic outcomes to follow a linear dose-response relation as adherence increased. 28 Primary independent variable. Perceived GHS was used as the primary independent variable of interest as described above. Responses were recategorized into 2 categories: "excellent/very good/good" and "fair/poor."
Covariates. The Mirowski and Ross sense of control (Cronbach's α = .68) and social support (Cronbach's α = .85) instruments were used as a mean score of 8 and 4 questions, respectively, with lower scores representing lower levels of both measures. 29, 30 The 10-question perceived stress scale was used to measure the degree to which situations in one's life are appraised as stressful (Cronbach's α = .84), with higher levels indicating higher stress. 31 Berger's HIV stigma scale, which includes 40 items rated on a 5-point scale from "strongly disagree" to "strongly agree," was used (Cronbach's α = .96), with higher scores representing more stigma. 32 Unfair treatment due to race was obtained from the Experiences of Discrimination instrument developed by Krieger et al (Cronbach's α = .37-.56), which characterized the participant as passive or active based on 2 questions dealing with how they would respond to being treated unfairly due to their race. [33] [34] [35] The Brief Substance Abuse Screener for Persons with HIV, which consists of 7 questions, was used for the study (κ = .30-.50; P < .001). 36 Also used was the Center for Epidemiologic Studies Depression Scale (Cronbach's α = .85-.90), 37 which measures current level of depressive symptomatology using 20 questions, with higher scores representing more depressive symptoms.
Statistical Analyses
All statistical analyses were performed using SPSS version 15.0 (SPSS, Inc., Chicago, Ill.). 38 Descriptive statistics are provided for all variables. Counts and frequencies are provided for categorical data, and means and standard deviations are provided for continuous variables. Independent samples t tests and χ 2 analyses were performed to test for differences in independent variables between adherent and nonadherent participants ( Table 1) . If an expected cell count was less than 5, Fisher's exact test was used instead of χ 2 . Logistic regression was performed and unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated ( Table 2) . Significance was assessed at the α = .05 level.
The multiple logistic regression model was assessed for multicollinearity and selected potential interactions. No collinear relationships or interactions were identified. A sensitivity analysis was conducted with substance abuse score because the scientific literature shows mixed results. 8 Substance abuse score was not included in the final model because it did not affect the relationship between general health and the other covariates with adherence. Data were missing for 9.7% of the sense of control score, 11.7% of the social support score, 7.8% of the stress score, and 16.5% of the HIV stigma score. Missing data were imputed for these variables using the individual mean imputation method, which imputes a value based on how a subject responds to other questions. This method was chosen because of its simplicity and accuracy. 39 Missing data were not imputed for unfair treatment (1.9% missing). There were no missing data for substance abuse score, age, gender, race/ethnicity, education, total number of medications, depression, or general health.
Results
Because adherence was the primary dependent variable and a qualitative valid survey instrument was used in the study, an internal validity measure Health Status and HAART Adherence / Cardarelli et al 125 against viral load counts was conducted to ensure that the instrument was valid in the study population. Our analysis found adherence to be highly associated with viral load (<.001), confirming it as a valid measure for the present study. Study population characteristics can be found in Table 1 . Overall, more than 70% of the study participants were found to be nonadherent to their HAART regimen. No significant differences in age, gender, race/ethnicity, education, sense of control, total number of medications, or substance abuse were found between adherent and nonadherent participants. Nonadherent participants had lower social support scores (P = .006), higher stress scores (P = .04), and higher depression symptomatology score (P = .005). Furthermore, a greater proportion of nonadherent participants reported their general health as "fair or poor" (P = .02) and reported as being passive when treated unfairly due to their race (P = .04). The difference in HIV stigma score between adherent and nonadherent participants approached significance (P = .09).
Univariate regression results are shown in Table 2 . Participants who rated their general health as poor/fair were more than 4 times more likely to be nonadherent when compared with those rating their health as good or better (OR, 4.34; 95% CI, 1.19-15.79). Additionally, for every 1-point increase in social support scores, participants were 25% less likely (OR, 0.75; 95% CI, 0.61-0.93) to be nonadherent to their HAART regimen. For every 1-point increase in the reported stress score, participants were 7% more likely to be nonadherent (OR, 1.07; 95% CI, 1.01-1.13). Every 1-point increase in the depression symptomatology score was also associated with a 5% increase in nonadherence (OR, 1.05; 95% CI, 1.01-1.10). Borderline associations were observed for unfair treatment due to race and HIV stigma scores. Participants who reported being passive when treated unfairly due to race were greater than 4 times more likely to be nonadherent (OR, 4.40; 95% CI, 0.95-20.36), and every 1-point increase in HIV stigma scores was associated with a 2% increase in the likelihood of being nonadherent (OR, 1.02; 95% CI, 1.00-1.01). Age, gender, race/ ethnicity, education, sense of control, substance abuse, and total number of medications were not found to be significantly associated with adherence. The final regression model is also presented in Table 2 . The results show that after accounting for sense of control, social support, perceived stress, HIV stigma, total number of medications, depression symptomatology, unfair treatment due to race, and sociodemographic variables (age, gender, race/ethnicity, and education), those who rated their general health as poor/fair were 11 times more likely to be nonadherent when compared with those who rated their health as good or better (OR, 10.96; 95% CI, 1. 46-82.36 ). None of the covariates remained significant in the final model.
Discussion
This is the first study that has assessed the association of perceived GHS and HAART adherence while taking into account various psychosocial factors known to affect adherence. The association between fair/poor GHS and nonadherence increased from an odds of 4.34 to 10.96 after controlling for the confounding effects of the covariates. Apart from adding to the literature of GHS's strength as a predictor of health outcomes, 25 this study opens the door to other potential research, especially the clinical utility of GHS. The significance of this study's findings are most likely due to GHS's ability to serve as a proxy, or better yet, a summative measure of psychosocial stress and its negative impact on health behavior. This is supported by extensive evidence that found GHS to be associated with several psychosocial factors and overall mortaility. 25, 26, 40 A meta-analytic study found persons with poor selfreported health (ie, GHS) had a 2-fold higher mortality risk when compared with those reporting excellent health. Another study found changes of perceived discrimination over time to be associated with changes in GHS. 41 A prospective cohort study of 2675 postmenopausal women found fair/poor GHS to be significantly associated with positive depression symptomatology. 42 Moreover, a general measure of perceived stress was found to correlate to poorer GHS among all racial/ethnic groups. 43 Because many of the psychosocial factors known to affect therapeutic adherence are also associated with perceived GHS, one can postulate whether GHS can be used to screen for nonadherence or, more important, assess potential causes. A national study of more than 13 000 noninstitutionalized Medicare enrollees found cost-related medication nonadherence to be 3.9 times greater (95% CI, 1.7-9.2) among those with poor GHS when compared with those with good GHS. 44 Another study found persons at high risk for hip fractures with low GHS to be 30% less likely to be adherent with recommended use of hip protectors. 45 These results parallel the findings of our current study, supporting this association.
GHS has been extensively studied in health services research, 25 but no one has suggested a potential clinical utility to this simple 1-question measure. Mental health and psychosocial barriers are highly underdiagnosed by clinicians, 46 which most likely has an impact on medication adherence for any medical condition. Hence, assessing an individual's perceived GHS can function as a facilitator to recognize and address nonadherence and underlying psychosocial factors. For example, a "poor/fair" response from the patient can be followed by an open-ended question by the clinician, "Why do you rate your health poor (or fair) and not excellent?" Responses may include nonmedical issues, such as the inability to pay for housing, but the clinician has the opportunity to counsel the patient to manage the stress and refer the patient to a social worker for assistance. The response can also be medically related, such as a loss of interest in life, which may lead to a diagnosis of depression and appropriate treatment. These actions can potentially address the underlying factors that are causing negative behavior, such as medication nonadherence, thus having an indirect positive effect. Simple efforts, such as incorporating a 1-question intervention, has a greater ability to be adopted and sustained in clinical practice if found beneficial. Clinicians are pressured to see high volumes of patients while expected to provide the highest quality of care. 47 Moreover, most studied interventions to improve HAART adherence are costly, such as hiring personnel to counsel patients, 16 which may be valid but unrealistic to public clinics with limited budgets.
There are several limitations of the study that are worth noting. The small sample size contributes to the wide confidence intervals observed in the study, placing the result's stability into question. The fact that statistical significance was achieved with the sample demonstrates that the study was sufficiently powered for the main predictor-GHS. The cross-sectional nature of the study precludes a cause-and-effect statement as well as a potential for reverse causality. Hence, randomized controlled trials and prospective studies are needed to address these limitations. Caution is advised when generalizing the results to other regions of the country because variability in study populations may exist. Because the study population was recruited from a county health department clinic serving an underserved populace, caution is even advised when generalizing the results beyond those served by the clinic.
Future studies are needed to assess the clinical utility of assessing GHS on improving medication adherence. The present study has taken the first step in establishing a relationship between nonadherence and GHS. Next steps include establishing a causal relationship and testing whether assessing GHS and intervening based on one's response improves outcomes (ie, HAART adherence and HIV/AIDS associated mortality).
